Browse SFTPA2

Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix. Secreted, extracellular space, surface film.
Domain PF00059 Lectin C-type domain
Function

In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration.

> Gene Ontology
 
Biological Process GO:0007585 respiratory gaseous exchange
Molecular Function GO:0030246 carbohydrate binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030141 secretory granule
GO:0042599 lamellar body
GO:0045334 clathrin-coated endocytic vesicle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
Reactome R-HSA-5619084: ABC transporter disorders
R-HSA-5683678: Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3)
R-HSA-5688890: Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
R-HSA-5688849: Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
R-HSA-5687868: Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF)
R-HSA-1643685: Disease
R-HSA-5687613: Diseases associated with surfactant metabolism
R-HSA-5668914: Diseases of metabolism
R-HSA-5619115: Disorders of transmembrane transporters
R-HSA-392499: Metabolism of proteins
R-HSA-5683826: Surfactant metabolism
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SFTPA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SFTPA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.67 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SFTPA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3720.124
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.3020.108
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7070.564
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.040.285
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.4830.069
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7880.618
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.7850.401
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5960.753
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.3690.237
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.310.477
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SFTPA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SFTPA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SFTPA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SFTPA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SFTPA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SFTPA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SFTPA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSFTPA2
Namesurfactant protein A2
Aliases SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ......
Chromosomal Location10q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SFTPA2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.